Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Addex Therapeutics (ADXN) Shares Outstanding (Weighted Average) (2018 - 2025)

Addex Therapeutics' Shares Outstanding (Weighted Average) history spans 8 years, with the latest figure at $185.0 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 26.3% to $185.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $185.0 million, a 26.3% increase, with the full-year FY2025 number at $178.3 million, up 21.75% from a year prior.
  • Shares Outstanding (Weighted Average) came in at $185.0 million for Q4 2025, up from $2.3 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $675.9 million in Q3 2022, with the low at $1.2 million in Q1 2023.
  • Historically, Shares Outstanding (Weighted Average) has averaged $78.8 million across 5 years, with a median of $42.5 million in 2021.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): surged 1159.44% in 2022 and later plummeted 99.76% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $41.1 million in 2021, then soared by 94.81% to $80.1 million in 2022, then surged by 76.28% to $141.1 million in 2023, then grew by 3.76% to $146.4 million in 2024, then increased by 26.3% to $185.0 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for ADXN at $185.0 million in Q4 2025, $2.3 million in Q3 2025, and $2.2 million in Q2 2025.